louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03495349: Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Official title: Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetic Foot Infection
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-04-12
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All of the patients followed and treated for diabetic foot infection in the 2 Endocrinology departments of Hospices Civils of Lyon. All of the patients have accepted to take part in the study.

Brief summary: Diabetes is a frequent and serious disease, with many complications. Diabetic foot ulcers are a frequent complication. Infection of diabetic foot ulcers is common, and requires heavy medical and/or surgical treatments. Antibiotherapy is one of the main options for the treatment of the diabetic foot ulcers, but it has many side effects.

The aim of this study is to evaluate effectiveness and safety of medical treatments, in this population of patients.


Eligibility criteria: Inclusion Criteria:

* Adults men and women
* Followed for diabetic foot infection (grades 2 to 4 of IWGDF classification)
* That accepted to take part in the study

Exclusion Criteria:

* Legal safeguard
* Pregnant women
* Patient that can't accept to take part in the study because can't be informed
* Exclusive surgical treatment

Primary outcomes:
measure: Effectiveness of adverse effects in patients treated by antibiotherapy for diabetic foot infection, assessed by clinical or biological methods
timeFrame: 1 year
measure: Occurrence of adverse effects in patients treated by antibiotherapy for diabetic foot infection, assessed by clinical or biological methods
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Groupement Hospitalier Est
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud
Study officials:
affiliation: Hospices Civils de Lyon
name: Julien Vouillarmet, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06919549: Results of Repair of Triangular Fibrocartilage Complex Tears Using Mini Anchor:
Official title: Results of Repair of Triangular Fibrocartilage Complex Tears Using Mini Anchor:
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Triangular Fibrocartilage Complex Tears
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-04-09
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Triangular fibrocartilage complex (TFCC) is a grouping of ligaments and cartilage in the wrist The TFCC is comprised of six major components: the distal radioulnar ligaments (dorsal and volar), central articular disk, meniscus homolog, ulnar collateral ligament, ECU subsheath, and the ulnolunate (UL)/ulnotriquetral (UT) ligaments.

This is important for wrist motion, stabilization, and overall hand function, including grip strength may progress to persistent pain, instability of the distal radioulnar joint, and arthritis if left untreated..

The TFCC vascularity is supplied by the anterior interosseous and ulnar arteries, although only a quarter of the TFCC is perfused. The limited vascularity of the TFCC, combined with its intricate soft tissue structure and torsional and axial stresses, makes the TFCC prone to frequent injury while maintaining a limited ability to heal.

Injuries like a fall on the outstretched hand or a forced ulnar deviation of the wrist can lead to an acute TFCC tear.

TFCC tears are a common cause of ulnar sided wrist pain and can be caused by chronic degeneration or traumatic injury.

Acute or chronic triangular fibrocartilage complex (TFCC) tears may result in persistent ulnar-sided wrist pain, loss of grip strength, and loss of function for patients.

A combination of clinical history, physical examination, and magnetic resonance imaging (MRI) may be used to diagnose a TFCC lesion, but confirmation of pathology requires an arthroscopic assessment. Arthroscopic assisted repair techniques have revolutionized surgical management Treatment of TFCC using mini anchor arthroscopically providing many benefits.

Functional outcome using Mayo wrist score after arthroscopic repair of triangular fibrocartilage complex tears using mini anchor


Eligibility criteria: Inclusion Criteria:

- Peripheral traumatic tears of triangular fibrocartilage complex in both sexes aged from teenagers to sixty.

b. Exclusion criteria:

1. Degenerative tears of triangular fibrocartilage complex. 2. Central- or radial-sided triangular fibrocartilage complex tears. 3. Tears associated with bony injuries.

-

Primary outcomes:
measure: Functional outcome using Mayo wrist score
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01133249: Total Hip Registry
Official title: Total Hip Registry
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteoarthritis
Keywords: total hip
Lead sponsor: Heekin Orthopedic Research Institute
Sponsor class: OTHER
Collaborators: name: Stryker Orthopaedics
name: DePuy Orthopaedics
name: Restor3D
First posted: 2010-05-28
Enrollment: 942
Sex: ALL
Minimum age (years): 21
Maximum age (years): 93
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population: All total hip replacements

Selection: Males and non-pregnant females over the age of 21

Brief summary: Objective

Describe the clinical and demographic characteristics of patients who undergo hip arthroplasty and document post operative outcomes.

Examine the relationship between processes of care, hospital and surgeon associated outcomes

Provide expanded data to characterize existing and evolving practice patterns, delivery of care, and resource utilization in the management of knee arthroplasty patients.

Analyze and design ancillary studies to address unanswered questions.

Disseminate findings through publication in peer-reviewed scientific journals.


Eligibility criteria: Inclusion Criteria:

* Patient requires total hip Arthroplasty
* Patient has signed IRB approved informed consent

Exclusion Criteria:

* Less than 21 years of age
* Patient is a prisoner

Primary outcomes:
measure: Harris Hip Score
timeFrame: 2 weeks, 6 weeks, 3 months, 6 months, 1, 2, 5, 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Heekin Orthopedic Specialists
state: Florida
Study officials:
affiliation: Heekin Orthopedic Specialists
name: Richard D Heekin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02990949: The Impact of the Timing of Trigger on IVF Success
Official title: The Impact of the Timing of Trigger on IVF Success: Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Fertilization in Vitro
Infertility
Embryonic Development
Lead sponsor: Colorado Center for Reproductive Medicine
Sponsor class: OTHER
Collaborators: name: Fertility Laboratories Of Colorado
First posted: 2016-12-13
Enrollment: 29
Sex: FEMALE
Minimum age (years): 26
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to examine the length of ovarian stimulation with the timing of trigger in an IVF cycle and its potential to impact patient outcomes.


Eligibility criteria: Inclusion Criteria:

* Planning to move forward with an IVF cycle
* Have met the requirements of being a patient at CCRM Colorado
* AMA: 39-44 years old And/or
* DOR: AMH \< 1 \& FSH \>10 (age independent)

Exclusion Criteria:

* Contraindication for pregnancy
* Have not fulfilled requirements for IVF cycle
* Single gene couple or chromosomal rearrangement
* Severe male factor or testicular surgical sperm removal (need sufficient sperm for ICSI)
* One ovary
* Uterine anomalies
* Stage III or IV endometriosis
* Explained recurrent miscarriage
* PCO or PCOS
* Using donor oocyte or gestational carrier

Primary outcomes:
measure: Euploid Embryos: the percentage of euploid embryos produced as analyzed by comprehensive chromosomal screening, of total embryos tested
timeFrame: 4 weeks after egg retrieval
Secondary outcomes:
measure: Egg maturation: the proportion of mature eggs of total number of eggs retrieved
timeFrame: 1 week after egg retrieval
measure: Live birth outcomes: the incidence of pregnancy resulting in live birth following embryo transfer of embryos produced by this IVF cycle
timeFrame: 9 months after frozen embryo transfer
Other outcomes:
Locations:
city: Lone Tree
country: United States
facility: Colorado Center for Reproductive Medicine
state: Colorado
Study officials:
affiliation: CCRM, FLC
name: Mandy Katz-Jaffe, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04859049: Single Injection Infromedial Peribulbar Injection in Lacrimal Duct
Official title: Assessing the Effect of Single Injection Infromedial Peribulbar Injection in Lacrimal Duct Intubation Surgery in Adult Patient: Prospective Cohort Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain Due to Certain Specified Procedures
Lead sponsor: Research Institute of Ophthalmology, Egypt
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: infromedial injection of 3 ml local anesthetic drugs and assessing the pain during lacrimal duct intubation and probability of false tracking

Detailed description: After entering the OR; the patient will be cannulated and fully monitored with basic monitors (pulse oximeter, NIBP \& ECG), a nasal cannula is connected to the patient to deliver oxygen.

We gave the patient 5 ml of propofol to decrease the discomfort felt by the patient during injection of local anesthesia. Benox eye drops is applied to the operative eye in both groups.

Patients were allocated into 2 groups; each group is 25 patients Group 1: We used a 25G/ 1" length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin.

Group 2: We used a 25G/ 1" length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection

During surgery, we will assess the pain degree during probing using Verbal Rating Scale (0 to 10 scale where 0 is no pain an 10 is unbearable pain), to assess the efficiency of this single low volume injection.

Eligibility criteria: Inclusion Criteria:

* adults undergoing lacrimal duct intubation surgery
* Patients' physical status by the American Association of Anesthesiology (ASA): ASA I, II, III.
* Age between 18-70, both sexes.
* Axial lengths ranging between 22-28mm.

Exclusion Criteria:

* ASA IV.
* Patient age less than 18 or more than 70 years.
* Coagulation disorders (e.g. patients on warfarin (INR\<1.5)
* Communication difficulties preventing reliable assessment.
* High myopia (axial length more than 28mm) and medial staphylomas.

Primary outcomes:
measure: Verbal rating scale (VRS) is a 5 point scale from 0 to 4 where 0 is no pain and 4 is unbearable pain
timeFrame: during surgery , study will started September 2021 & will end November 2022
Secondary outcomes:
measure: surgery satisfaction using yes or no questionnaire
timeFrame: during surgery
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Research Institute of Ophthamology
city: Giza
country: Egypt
facility: Research Institute of Ophthalmology
Study officials:
affiliation: research institute of ophthalmology
name: abeer salem, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01840449: Somatuline Predictive Factors in Acromegaly and NET
Official title: Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acromegaly
Neuroendocrine Tumours
Lead sponsor: Ipsen
Sponsor class: INDUSTRY
First posted: 2013-04-25
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Clinics and private practitioners who treat acromegaly and/or NET subjects with Somatuline Autogel® 60, 90 or 120 mg.

Brief summary: The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.


Eligibility criteria: Inclusion Criteria:

* Written informed consent (also mandatory in case of retrospective documentation of subject data)
* Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG

Exclusion Criteria:

* The subject has already been included in this study
* Participation in an interventional trial

Primary outcomes:
measure: Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)
timeFrame: Baseline and 1 year
Secondary outcomes:
measure: Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)
timeFrame: Baseline and 2 years
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: University Hospital of Vienna
city: Hamburg
country: Germany
facility: ENDOC
city: Basel
country: Switzerland
facility: University Hospital Basel
Study officials:
affiliation: Ipsen
name: Ipsen Medical Director
role: STUDY_DIRECTOR
References:
citation: Rinke A, Maintz C, Muller L, Weber MM, Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H, Petersenn S. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Exp Clin Endocrinol Diabetes. 2021 Jul;129(7):500-509. doi: 10.1055/a-1342-2755. Epub 2021 Jul 22.
Clinical trial NCT00576849: A Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients
Official title: Phase 4 Study of a Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Elderly
Cardiac Surgery
Lead sponsor: Klinikum Ludwigshafen
Sponsor class: OTHER
First posted: 2007-12-19
Enrollment: 50
Sex: ALL
Minimum age (years): 80
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A total balanced fluid replacement strategy is a promising concept for correcting hypovolemia. The effects of a balanced fluid management including a new balanced hydroxyethylstarch (HES) in elderly cardiac surgery patients will be studied.


Eligibility criteria: Inclusion Criteria:

* Patients aged \>80 years

Exclusion Criteria:

* Chronic kidney dysfunction requiring dialysis
* Myocardial infarction within the previous 3 weeks
* Liver insufficiency

Primary outcomes:
measure: The primary endpoint of the study is postoperative renal function
timeFrame: 28 days
Secondary outcomes:
measure: Other organ function (myocardial function, endothelial function, degree of inflammation)
timeFrame: Postoperative period
Other outcomes:
Locations:
city: Ludwigshafen
country: Germany
facility: Klinikum Ludwigshafen
state: RLP
Study officials:
affiliation: Klinikum Ludwigshafen
name: Joachim Boldt, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06056349: Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center
Official title: An Open Label Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cluster Seizure
Keywords: seizure cluster
epilepsy
rescue medication
benzodiazepines
Lead sponsor: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Sponsor class: OTHER
First posted: 2023-09-28
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: This is an open label, randomnized, prospective clinical trial, with a 1:1:1 aleatorization of a single third level specialized neurological center.
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the efficacy in seizure reduction when comparing orodispersable clonazepam versus usual treatment (i.e. medication load, intravenous high- dose benzodiazepines) of seizure clusters in a third level center of care in Mexico city.

Detailed description: This is an open label, randomized, prospective clinical trial, with a 1:1:1 aleatorization of a single third level specialized neurological center.

Primary objective: To evaluate the clinical impact of the use of buccal midazolam as a treatment of seizure clusters in comparison with orodispersable clonazepam vs usual care.

Secondary objective: To identify patients that present seizure clusters and risk factors associated with the diagnosis. To evaluate the quality of life after drug administration, to evaluate the adverse events associated with the medications. To establish seizure recurrence and mortality in 6 months' follow up.

Eligibility criteria: Inclusion Criteria:

* At least age of 18
* Patient available for follow-up
* Previous diagnosis of epilepsy
* Patient meets criteria for seizure clusters (3 or more seizures in a period of 24 hours)

Exclusion Criteria:

* Risk factors for epilepsy have been identified and uncontrolled.
* Younger than 18 years olf
* Follow- up in another healthcare unit
* No previous epilepsy diagnosis
* Adequate control of epilepsy
* Patient meets criteria for clinical or electrographic status epilepticus.

Primary outcomes:
measure: Change from baseline seizure frequency comparison using buccal midazolam, orodispersable clonazepam versus usual care efficacy for seizure clusters
timeFrame: 1,3 and 6 months
Secondary outcomes:
measure: Change from baseline seizure recurrence in 6 months
timeFrame: 6 months
measure: Change from baseline quality of life assessed by the QOLIE-31 from baseline
timeFrame: 6 months
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Instituto Nacional de Neurología y Neurocirugía "Dr. Manuel Velasco Suárez"
state: Cdmx
Study officials:
affiliation: National Institute of Neurology and Neurosurgery
name: Elma M Paredes-Aragón, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01826149: Propofol Effects on Mitral Valve Annular Velocity
Official title: The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Valvular Heart Disease
Coronary Artery Disease
Lead sponsor: Konkuk University Medical Center
Sponsor class: OTHER
First posted: 2013-04-08
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is primarily to determine the effects of propofol at different concentration on the mitral valve annulus by using Tissue Doppler Imaging

Detailed description: The purpose of this study is to evaluate the effects of different concentration of propofol on patients who are undergoing cardiac surgery. The patients will receive infusion remifentanil 0.5mcg/kg/min with different target-site propofol concentration namely 1.0ng/ml, 2.0ng/ml and 3.0ng/ml. Tissue Doppler Imaging by transesophageal echocardiography will be done to assess the changes in cardiac function.

Eligibility criteria: Inclusion Criteria:

patients undergoing cardiac surgery

Exclusion Criteria:

low ejection fraction \< 50% on transthoracic echocardiography atrial fibrillation pacemaker pericardial and infiltrative myocardial disease mitral annular calcification, surgical rings, prosthetic mitral valve lateral left ventricular wall motion abnormality oesophageal abnormality history of extensive radiation to the mediastinum upper gastrointestinal bleeding

Primary outcomes:
measure: Change of systolic mitral valve annular velocity (S')
timeFrame: 10 min after achieving 3 different propofol concentrations
Secondary outcomes:
measure: Early diastolic mitral valve annular velocity (e')
timeFrame: 10 min after achieving 3 different propofol concentrations
measure: late diastolic (atrial contractile) mitral valve annular velocity (a')
timeFrame: 10 min after achieving 3 different propofol concentrations
measure: ejection fraction
timeFrame: 10 min after achieving 3 different propofol concentrations
measure: phenylephrine infusion rate
timeFrame: 10 min after achieving 3 different propofol concentrations
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Konkuk University Medical Center
Study officials:
affiliation: Konkuk University Medical Center, Seoul, Korea, Republic of
name: Tae-yop Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bang JY, Kim S, Choi BM, Kim TY. Pharmacodynamic Analysis of the Influence of Propofol on Left Ventricular Long-Axis Systolic Performance in Cardiac Surgical Patients. J Korean Med Sci. 2019 Apr 29;34(16):e132. doi: 10.3346/jkms.2019.34.e132.
Clinical trial NCT01299649: Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®
Official title: A Retrospective Observational Database Study To Compare In-Hospital All-Cause Mortality in Critically Ill Patients Undergoing Echocardiography With or Without DEFINITY®
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Disease
Keywords: CAD
Lead sponsor: Lantheus Medical Imaging
Sponsor class: INDUSTRY
First posted: 2011-02-18
Enrollment: 4300000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All that received an echocardiogram

Brief summary: Retrospective analysis to observe changes in short term mortality


Eligibility criteria: Inclusion Criteria:

* Males and females
* At least 18 years of age

Primary outcomes:
measure: Short term mortality
timeFrame: 48 hours post echo produre
Secondary outcomes:
Other outcomes:
Locations:
city: N. Billerica
country: United States
facility: Lantheus Medical Imaging
state: Massachusetts
Study officials:
References: